Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma

BACKGROUND: Lenvatinib is used for unresectable hepatocellular carcinoma (u-HCC) as first-line, as well as second- and third-line therapy in Japan. We evaluated the therapeutic efficacy of newly developed ramucirumab when given after lenvatinib for post-progression treatment. METHODS: Of 385 patient...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Gastroenterol Rep (Oxf)
Prif Awduron: Hiraoka, Atsushi, Kumada, Takashi, Tada, Toshifumi, Ogawa, Chikara, Tani, Joji, Fukunishi, Shinya, Atsukawa, Masanori, Hirooka, Masashi, Tsuji, Kunihiko, Ishikawa, Toru, Takaguchi, Koichi, Kariyama, Kazuya, Itobayashi, Ei, Tajiri, Kazuto, Shimada, Noritomo, Shibata, Hiroshi, Ochi, Hironori, Kawata, Kazuhito, Toyoda, Hidenori, Ohama, Hideko, Nouso, Kazuhiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Hayama, Korenobu, Arai, Taeang, Imai, Michitaka, Koizumi, Yohei, Nakamura, Shinichiro, Michitaka, Kojiro, Hiasa, Yoichi, Kudo, Masatoshi
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2020
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8128005/
https://ncbi.nlm.nih.gov/pubmed/34026220
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/gastro/goaa042
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg